Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Liver function tests and absolute lymphocyte count at day +100 are predictive factors for extensive and severe chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant.

Silva F, Pérez-Simón JA, Caballero Velazquez T, Encinas C, Sánchez-Guijo FM, Díez-Campelo M, Colado E, Martín J, Villanueva-Gomez F, Vazquez L, Del Cañizo C, Caballero D, San Miguel J.

Am J Hematol. 2010 Apr;85(4):290-3. doi: 10.1002/ajh.21613. No abstract available.

2.

One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.

Mengarelli A, Iori AP, Romano A, Cerretti R, Cerilli L, De Propris MS, Fenu S, Moleti ML, De Felice L, Girelli G, Arcese W.

Haematologica. 2003 Mar;88(3):315-23.

3.

Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation.

Dhédin N, Chamakhi I, Perreault C, Roy DC, Sauvageau G, Ducruet T, Busque L, Fish D, Bélanger R, Roy J.

Exp Hematol. 2006 Jan;34(1):107-14.

PMID:
16413397
4.
5.

B-cell concentration in the apheretic product predicts acute graft-versus-host disease and treatment-related mortality of allogeneic peripheral blood stem cell transplantation.

Iori AP, Torelli GF, De Propris MS, Milano F, Pupella S, Gozzer M, Mancini F, Milani ML, Intoppa S, Cerretti R, Lucarelli B, Valle V, Malandruccolo L, Iannella E, Arleo E, Guarini A, Foà R.

Transplantation. 2008 Feb 15;85(3):386-90. doi: 10.1097/TP.0b013e3181622e36.

PMID:
18322430
6.

CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.

Mohty M, Bagattini S, Chabannon C, Faucher C, Bardou VJ, Bilger K, Vey N, Gaugler B, Stoppa AM, Coso D, Ladaique P, Olive D, Viens P, Blaise D.

Exp Hematol. 2004 Nov;32(11):1097-102.

PMID:
15539088
7.

Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen.

Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O, Vey N, Stoppa AM, Coso D, Chabannon C, Viens P, Maraninchi D, Blaise D.

Blood. 2003 Jul 15;102(2):470-6. Epub 2003 Mar 20.

9.

Prognostic value of T-1 cell numbers prior to allogeneic stem cell transplantation in patients with severe graft-versus-host disease.

Banning U, Lange T, Krahl R, Mauz-Körholz C, Krutmann J, Niederwieser D, Körholz D.

Bone Marrow Transplant. 2005 Apr;35(7):691-7.

PMID:
15696178
10.

Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation.

Pavletic SZ, Smith LM, Bishop MR, Lynch JC, Tarantolo SR, Vose JM, Bierman PJ, Hadi A, Armitage JO, Kessinger A.

Am J Hematol. 2005 Apr;78(4):265-74.

11.

Peripheral blood eosinophilia has a favorable prognostic impact on transplant outcomes after allogeneic peripheral blood stem cell transplantation.

Kim DH, Popradi G, Xu W, Gupta V, Kuruvilla J, Wright J, Messner HA, Lipton JH.

Biol Blood Marrow Transplant. 2009 Apr;15(4):471-82. doi: 10.1016/j.bbmt.2009.01.003.

12.
13.

Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study.

Gallardo D, de la Cámara R, Nieto JB, Espigado I, Iriondo A, Jiménez-Velasco A, Vallejo C, Martín C, Caballero D, Brunet S, Serrano D, Solano C, Ribera JM, de la Rubia J, Carreras E.

Haematologica. 2009 Sep;94(9):1282-8. doi: 10.3324/haematol.2009.006924.

14.

A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections.

Anderson D, DeFor T, Burns L, McGlave P, Miller J, Wagner J, Weisdorf D.

Biol Blood Marrow Transplant. 2003 Jan;9(1):52-9.

15.

Immunomonitoring of graft-versus-host minor histocompatibility antigen correlates with graft-versus-host disease and absence of relapse after graft.

Laurin D, Hannani D, Pernollet M, Moine A, Plumas J, Bensa JC, Cahn JY, Garban F.

Transfusion. 2010 Feb;50(2):418-28. doi: 10.1111/j.1537-2995.2009.02440.x. Epub 2009 Oct 15.

PMID:
19843288
16.

T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome.

Montero A, Savani BN, Shenoy A, Read EJ, Carter CS, Leitman SF, Mielke S, Rezvani K, Childs R, Barrett AJ.

Biol Blood Marrow Transplant. 2006 Dec;12(12):1318-25.

17.

CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans.

Stanzani M, Martins SL, Saliba RM, St John LS, Bryan S, Couriel D, McMannis J, Champlin RE, Molldrem JJ, Komanduri KV.

Blood. 2004 Feb 1;103(3):1140-6. Epub 2003 Aug 7.

18.

Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program.

Ozawa S, Nakaseko C, Nishimura M, Maruta A, Cho R, Ohwada C, Sakamaki H, Sao H, Mori S, Okamoto S, Miyamura K, Kato S, Kawase T, Morishima Y, Kodera Y; Japan Marrow Donor Program.

Br J Haematol. 2007 Apr;137(2):142-51.

PMID:
17391494
19.

Plasmacytoid dendritic cell count on day 28 in HLA-matched related allogeneic peripheral blood stem cell transplant predicts the incidence of acute and chronic GVHD.

Rajasekar R, Mathews V, Lakshmi KM, Sellathamby S, George B, Viswabandya A, Daniel D, Chandy M, Srivastava A.

Biol Blood Marrow Transplant. 2008 Mar;14(3):344-50. doi: 10.1016/j.bbmt.2007.12.494.

20.

Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Remberger M, Kumlien G, Aschan J, Barkholt L, Hentschke P, Ljungman P, Mattsson J, Svennilson J, Ringdén O.

Biol Blood Marrow Transplant. 2002;8(12):674-82.

PMID:
12523580

Supplemental Content

Support Center